Cargando…
Investigation into the Formation of Impurities during the Optimization of Brigatinib
[Image: see text] During the process development of brigatinib, we have made an unusual observation about some impurities. Detailed investigation has led to the conclusion that impurity A is formed via the raw material 2 oxidation, impurity B is formed via the pyrolysis of DMF, impurity C is formed...
Autores principales: | Guo, Aofeng, Zhang, Qiankun, Zhang, Junming, Chen, Jiale, Chen, Jiaqi, Sha, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676304/ https://www.ncbi.nlm.nih.gov/pubmed/33225157 http://dx.doi.org/10.1021/acsomega.0c03816 |
Ejemplares similares
-
Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies
por: Li, Bo, et al.
Publicado: (2019) -
Brigatinib for non-small cell lung cancer
Publicado: (2020) -
Effect of severe renal impairment on the pharmacokinetics of brigatinib
por: Gupta, Neeraj, et al.
Publicado: (2021) -
Brigatinib pharmacokinetics in patients with chronic hepatic impairment
por: Hanley, Michael J., et al.
Publicado: (2023) -
Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy
por: Zhang, Zhe, et al.
Publicado: (2019)